BioCryst Pharma (BCRX) Posts Narrower than Expected Q1 Loss of 13c/Share; Reaffirms

May 7, 2012 6:32 AM EDT Send to a Friend
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q1 EPS of ($0.13), $0.13 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $5.9 million.

BioCryst Pharmaceuticals, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment